Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia

Research Opportunity
PhD, Masters by Research, Honours, Master of Biomedical Science
Project Status
Future
Department
Medicine and Radiology
Location
Royal Melbourne Hospital
Supervisor Email Number Webpage
Professor Terence O'Brien obrientj@unimelb.edu.au 8344 5490 Personal web page
Professor Dennis Velakoulis dennisv@unimelb.edu.au Personal web page

Project Details

Frontotemporal dementia (FTD) is generally due to abnormalities either in a protein called tau (45%) or a protein called TDP-43 (45%). In both types of FTD the protein aggregates into ‘clumps’ that block brain cell function. There are currently no treatments for either type of FTD.

Our group has successfully run several research trials using a drug called sodium selenate that prevents the aggregation of tau in brain cells. We have shown that sodium selenate is safe in humans and that it has measurable benefits in Alzheimers disease (a different type of dementia to FTD). This study is an early phase study in which participants with FTD receive sodium selenate and are followed over 12 months. During this period standardised measurements of safety, cognition and neuroimaging (MRI, PET) will be undertaken.

Research Opportunities

This research project is available to PhD, Masters by Research, Honours, Master of Biomedical Science students to join as part of their thesis.
Please contact the supervisor to discuss your options.



Faculty Research Themes

Neuroscience

School Research Themes

Neuroscience & Psychiatry



Key Contact

For further information about this research, please contact a supervisor.

Department

Medicine and Radiology

Research Node

Royal Melbourne Hospital